RAND

Rand Capital Corp. (RAND) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Rand Capital Corporation is an externally managed, closed-end, non-diversified management investment company regulated as a Business Development Company (BDC) and taxed as a Regulated Investment Company (RIC). The company invests primarily in higher-yielding debt and equity instruments of lower middle-market companies. As of June 30, 2026, there were 2,969,814 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Investment Income Decline: Total investment income decreased 27.0% for the six months ended June 30, 2026, compared to the same period in 2025. This was primarily driven by a 26.2% decrease in interest from portfolio companies due to several investments (Autotality, FSS, ITA, MRES, and Swanson) being placed on non-accrual status.
• Expense Volatility: Total expenses for the six months ended June 30, 2026, were $1,289,307, compared to a net benefit of ($73,094) in the prior year. The prior year included a $1,565,000 benefit from the reversal of a capital gains incentive fee accrual. The current period had no such reversal.
• Portfolio Valuation: Net unrealized depreciation increased by $2,377,667 for the six months ended June 30, 2026. Significant unrealized losses were recorded for Swanson (ceased operations), Autotality, and Seybert's. Conversely, unrealized gains were recorded for Verta, All About People, and EFINEA.
• Liquidity Position: Cash and cash equivalents decreased from $4.2 million at December 31, 2025, to $429,639 at June 30, 2026. The company drew $5.1 million on its revolving credit facility during the period to fund new investments and operations.

Guidance, Outlook, and Risks

• Dividend Policy: The Board declared a quarterly cash dividend of $0.29 per share for the third quarter of 2026, payable in September 2026. The company maintains its RIC status to avoid corporate-level taxes.
• Capital Gains Fee: Under GAAP, the company accrues capital gains incentive fees based on net realized and unrealized gains. As of June 30, 2026, no fee was due based on net portfolio depreciation, though GAAP accruals may differ from actual payable amounts.
• Controls and Procedures: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to a material weakness in controls related to the accounting for income taxes and related disclosures. Remediation efforts are underway, including engaging a new third-party tax advisory firm.
• Investment Strategy: The company continues to focus on higher-yielding debt instruments. New investments in the period included Feature Healthcare, AME Holdco, and Termite Guy Corporation.

Key Facts for Investor Verification

• Non-Accrual Status: Verify the status and recovery prospects of the five debt investments placed on non-accrual status (Autotality, FSS, ITA, MRES, Swanson), which significantly impacted interest income.
• Material Weakness Remediation: Monitor the progress of remediation regarding the material weakness in income tax accounting controls disclosed in Item 4.
• Credit Facility Utilization: Note that $5.1 million is drawn on the $25 million credit facility, with an interest rate of 7.18% as of June 30, 2026. Verify compliance with the 3:1 asset coverage ratio covenant.
• Unrealized Losses: Review the specific valuation adjustments for Swanson (ceased operations) and Autotality, which contributed significantly to the period's unrealized depreciation.
• Share Repurchase Plan: A $1.5 million share repurchase plan was authorized in April 2026; verify if any shares were repurchased during the period (none were).